EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Kezar Life Sciences's Enterprise Value is $-82.01 Mil.
Kezar Life Sciences's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 was $-76.37 Mil. Therefore, Kezar Life Sciences's EV-to-FCF for today is 1.07.
The historical rank and industry rank for Kezar Life Sciences's EV-to-FCF or its related term are showing as below:
KZR'
s EV-to-FCF Range Over the Past 10 Years
Min: 1.07 Med: 1.33 Max: 1.82
Current: 1.07
During the past 8 years, the highest EV-to-FCF of Kezar Life Sciences was 1.82. The lowest was 1.07. And the median was 1.33.
KZR's EV-to-FCF is ranked better than 63.82% of 387
companies
in the Biotechnology industry
Industry Median: 8.7
vs KZR: 1.07
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
The historical data trend for Kezar Life Sciences's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Kezar Life Sciences's EV-to-FCF
For the Biotechnology subindustry, Kezar Life Sciences's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kezar Life Sciences's EV-to-FCF Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Kezar Life Sciences's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Kezar Life Sciences's EV-to-FCF falls into.
Kezar Life Sciences's current Enterprise Value is $-82.01 Mil.
Kezar Life Sciences's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-76.37 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kezar Life Sciences (NAS:KZR) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Kezar Life Sciences's PE Ratio (TTM) for today is calculated as:
Kezar Life Sciences's share price for today is $6.75.
Kezar Life Sciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-13.180.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Kezar Life Sciences EV-to-FCF Related Terms
Thank you for viewing the detailed overview of Kezar Life Sciences's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Kezar Life Sciences Inc is a clinical-stage biotechnology company. It is engaged in discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer. The pipeline consist of product candidates such as Zetomipzomib (KZR-616), and KZR-261.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
KZR has been successfully added to your 